|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
EBSCO_on1317842418 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
220518s2021 au o 000 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d EBLCP
|d N$T
|d OCLCF
|d OCLCQ
|d OCLCO
|
| 020 |
|
|
|a 9789201291202
|q (electronic bk.)
|
| 020 |
|
|
|a 9201291205
|q (electronic bk.)
|
| 035 |
|
|
|a (OCoLC)1317842418
|
| 050 |
|
4 |
|a RC78.7.T62
|
| 082 |
0 |
4 |
|a 616.07575
|2 23
|
| 049 |
|
|
|a UAMI
|
| 110 |
2 |
|
|a International Atomic Energy Agency,
|e issuing body.
|
| 245 |
1 |
0 |
|a Atlas of non-FDG PET--CT in diagnostic oncology.
|
| 264 |
|
1 |
|a Vienna :
|b International Atomic Energy Agency,
|c 2021.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
0 |
|
|a IAEA human health series ;
|v no. 38
|
| 505 |
0 |
|
|a Intro -- 1. INTRODUCTION -- 1.1. Background -- 1.2. Objective -- 1.3. Scope -- 1.4. Structure -- 2. ACETATE (11C) -- 2.1. General characteristics -- 2.2. Pharmacokinetics -- 2.2.1. Physiological biodistribution and metabolism -- 2.2.2. Mechanism of retention -- 2.2.3. Pharmacology and toxicology -- 2.3. Methodology -- 2.3.1. Activity, administration, dosimetry -- 2.3.2. Imaging protocol -- 2.4. Clinical aspects -- 2.4.1. Indications -- 3. Bevacizumab (89Zr) -- 3.1. General characteristics -- 3.2. Pharmacokinetics -- 3.2.1. Metabolism -- 3.2.2. Mechanism of retention
|
| 505 |
8 |
|
|a 3.2.3. Pharmacology and toxicology -- 3.3. Methodology -- 3.3.1. Activity, administration, dosimetry -- 3.3.2. Imaging protocol -- 3.4. Clinical aspects -- 3.4.1. Indications -- 4. Choline (11C) -- 4.1. General characteristics -- 4.2. Pharmacokinetics -- 4.2.1. Physiological biodistribution and metabolism -- 4.2.2. Mechanism of retention -- 4.2.3. Pharmacology and toxicology -- 4.3. Methodology -- 4.3.1. Activity, administration, dosimetry -- 4.3.2. Imaging protocol -- 4.4. Clinical aspects -- 4.4.1. Indications -- 5. Choline (18F) -- 5.1. General characteristics -- 5.2. Pharmacokinetics
|
| 505 |
8 |
|
|a 5.2.1. Physiological biodistribution and metabolism -- 5.2.2. Mechanism of retention -- 5.2.3. Pharmacology and toxicology -- 5.3. Methodology -- 5.3.1. Activity, administration, dosimetry -- 5.3.2. Imaging protocol -- 5.4. Clinical aspects -- 5.4.1. Indications -- 6. FLUORO-DIHYDROTESTOSTERONE -- FDHT (18F) -- 6.1. General characteristics -- 6.2. Pharmacokinetics -- 6.2.1. Physiological biodistribution and metabolism -- 6.2.2. Mechanism of retention -- 6.2.3. Pharmacology and toxicology -- 6.3. Methodology -- 6.3.1. Activity, administration, dosimetry -- 6.3.2. Imaging protocol
|
| 505 |
8 |
|
|a 6.4. Clinical aspects -- 6.4.1. Indications -- 7. F-DOPA (18F) -- 7.1. General characteristics -- 7.2. Pharmacokinetics -- 7.2.1. Physiological biodistribution and metabolism -- 7.2.2. Mechanism of retention -- 7.3. Methodology -- 7.3.1. Activity, administration, dosimetry -- 7.3.2. Imaging protocol -- 7.4. Clinical aspects -- 7.4.1. Indications -- 8. Fluoroestradiol, FES (18F) -- 8.1. General characteristics -- 8.2. Pharmacokinetics -- 8.2.1. Physiological biodistribution and metabolism -- 8.2.2. Mechanism of retention -- 8.2.3. Pharmacology and toxicology -- 8.3. Methodology
|
| 505 |
8 |
|
|a 8.3.1. Activity, administration, dosimetry -- 8.3.2. Imaging protocol -- 8.4. Clinical aspects -- 8.4.1. Indications -- 9. Fluoroethyl-tyrosine, FET (18F) -- 9.1. General characteristics -- 9.2. Pharmacokinetics -- 9.2.1. Physiological biodistribution and metabolism -- 9.2.2. Mechanism of retention -- 9.2.3. Pharmacology and toxicology -- 9.3. Methodology -- 9.3.1. Activity, administration, dosimetry -- 9.3.2. Imaging protocol -- 9.4. Clinical aspects -- 9.4.1. Indications -- 10. FLUOROTHYMIDINE, FLT (18F) -- 10.1. General characteristics -- 10.2. Pharmacokinetics
|
| 588 |
0 |
|
|a Vendor-supplied metadata.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Tomography, Emission.
|
| 650 |
|
0 |
|a Tomography.
|
| 650 |
|
0 |
|a Cancer
|x Radionuclide imaging.
|
| 650 |
|
0 |
|a Oncology.
|
| 650 |
|
2 |
|a Tomography, Emission-Computed
|
| 650 |
|
2 |
|a Medical Oncology
|
| 650 |
|
6 |
|a Tomographie par émission.
|
| 650 |
|
6 |
|a Tomographie.
|
| 650 |
|
6 |
|a Cancer
|x Scintigraphie.
|
| 650 |
|
6 |
|a Cancérologie.
|
| 650 |
|
7 |
|a Cancer
|x Radionuclide imaging
|2 fast
|
| 650 |
|
7 |
|a Oncology
|2 fast
|
| 650 |
|
7 |
|a Tomography
|2 fast
|
| 650 |
|
7 |
|a Tomography, Emission
|2 fast
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3282322
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL6985953
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 3282322
|
| 994 |
|
|
|a 92
|b IZTAP
|
